Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Louise Farecki

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Klinische Monatsblatter Fur Augenheilkunde|September 13, 2017
[Exudative AMD in OCT Angiography]Marie-Louise Farecki, Matthias Gutfleisch, Henrik Faatz, et al.
BMJ Open Ophthalmology|January 8, 2020
Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatmentHenrik Faatz, Marie-Louise Farecki, Kai Rothaus, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 27, 2019
[Are There Different Phenotypes in Geographic Atrophy of AMD? - Pilot Study on Differentiation Using Multimodal Imaging]Ioannis Papapostolou, Albrecht Peter Lommatzsch, Marie-Louise Farecki, et al.
Klinische Monatsblatter Fur Augenheilkunde|September 13, 2017
[OCT Angiography in Exudative AMD with Detachment of Vascularised Retinal Pigment Epithelium]Frederic Gunnemann, Kai Rothaus, Marie-Louise Farecki, et al.
Eye (London, England)|April 12, 2019
Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative methodHenrik Faatz, Marie-Louise Farecki, Kai Rothaus, et al.
Klinische Monatsblatter Fur Augenheilkunde|October 26, 2019
[Analysis of the "Portal" Care Model - Examination of the Outcome Quality of IVOM Therapy with Regard to Latency Periods in Exudative AMD]Kai Rothaus, Marie-Louise Farecki, Peter Mussinghoff, et al.
Retina (Philadelphia, Pa.)|December 15, 2015
RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term PrognosisBritta Heimes, Marie-Louise Farecki, Sina Bartels, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 25, 2017
Characteristics of type 1 and 2 CNV in exudative AMD in OCT-AngiographyMarie-Louise Farecki, Matthias Gutfleisch, Henrik Faatz, et al.
Klinische Monatsblatter Fur Augenheilkunde|September 13, 2017
[Changes in OCT Angiography of Type 2 CNV in Neovascular AMD during Anti-VEGF Treatment]Henrik Faatz, Kai Rothaus, Frederic Gunnemann, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2009
Neurological symptoms in patients with biopsy proven celiac diseaseKatrin Bürk, Marie-Louise Farecki, Georg Lamprecht, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Klinische Monatsblatter Fur Augenheilkunde|September 13, 2017
[Exudative AMD in OCT Angiography]Marie-Louise Farecki, Matthias Gutfleisch, Henrik Faatz, et al.
BMJ Open Ophthalmology|January 8, 2020
Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatmentHenrik Faatz, Marie-Louise Farecki, Kai Rothaus, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 27, 2019
[Are There Different Phenotypes in Geographic Atrophy of AMD? - Pilot Study on Differentiation Using Multimodal Imaging]Ioannis Papapostolou, Albrecht Peter Lommatzsch, Marie-Louise Farecki, et al.
Klinische Monatsblatter Fur Augenheilkunde|September 13, 2017
[OCT Angiography in Exudative AMD with Detachment of Vascularised Retinal Pigment Epithelium]Frederic Gunnemann, Kai Rothaus, Marie-Louise Farecki, et al.
Eye (London, England)|April 12, 2019
Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative methodHenrik Faatz, Marie-Louise Farecki, Kai Rothaus, et al.
Klinische Monatsblatter Fur Augenheilkunde|October 26, 2019
[Analysis of the "Portal" Care Model - Examination of the Outcome Quality of IVOM Therapy with Regard to Latency Periods in Exudative AMD]Kai Rothaus, Marie-Louise Farecki, Peter Mussinghoff, et al.
Retina (Philadelphia, Pa.)|December 15, 2015
RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term PrognosisBritta Heimes, Marie-Louise Farecki, Sina Bartels, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 25, 2017
Characteristics of type 1 and 2 CNV in exudative AMD in OCT-AngiographyMarie-Louise Farecki, Matthias Gutfleisch, Henrik Faatz, et al.
Klinische Monatsblatter Fur Augenheilkunde|September 13, 2017
[Changes in OCT Angiography of Type 2 CNV in Neovascular AMD during Anti-VEGF Treatment]Henrik Faatz, Kai Rothaus, Frederic Gunnemann, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2009
Neurological symptoms in patients with biopsy proven celiac diseaseKatrin Bürk, Marie-Louise Farecki, Georg Lamprecht, et al.
Pageof 2